Skip to content

Pacific Biosciences of California, Inc.

PACB· NasdaqCore metricsCIK 1299130

Laboratory analytical instruments24 peers

Last sale
Nov 12, 2026 · -5.52%
Market cap
$616.47M
312.93M shares
Filings
978
$40.56M
Q3 2026+3.9% FY25 yoy
-$37.85M
Q3 2026N/M FY25 yoy
-$37.00M
Q3 2026N/M FY25 yoy
-$123.47M
Q3 2026derivedN/M FY25 yoy
-$0.12
Q3 2026N/M FY25 yoy
$55.91M
Q3 2026+15.1% FY25 yoy
$616.47M
—
3.8×
—
-23.26%
—

Twelve months to Sep 30, 2026 · derived

Price

$1.97+5.91%+$0.11past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$160.01MFY 2025
$200.52M0FY 2014FY 2019FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$160,005,000reported
FY 20242024-12-31$154,014,000reported
FY 20232023-12-31$200,521,000reported
FY 20222022-12-31$128,304,000reported
FY 20212021-12-31$130,513,000reported
FY 20202020-12-31$78,893,000reported
FY 20192019-12-31$90,891,000reported
FY 20182018-12-31$78,626,000reported
FY 20172017-12-31$93,468,000reported
FY 20162016-12-31$90,714,000reported
FY 20152015-12-31$92,782,000reported
FY 20142014-12-31$60,594,000reported

Capital returns

Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2009—$8.00K$8.00K————

Segments

Revenue by Geography, FY2018 to FY2025FY2018Asia-Pacific · FY2018 · $29.07MAmericas · FY2018 · $35.60MEurope, Middle East, and Africa · FY2018 · $13.96MFY2019Asia-Pacific · FY2019 · $26.61MAmericas · FY2019 · $44.68MEurope, Middle East, and Africa · FY2019 · $19.60MFY2020Asia-Pacific · FY2020 · $22.55MAmericas · FY2020 · $37.28MEurope, Middle East, and Africa · FY2020 · $19.07MFY2021Asia-Pacific · FY2021 · $35.72MAmericas · FY2021 · $64.52MEurope, Middle East, and Africa · FY2021 · $30.27MFY2022Americas · FY2022 · $69.56MUnited States · FY2022 · $66.80MEurope, Middle East, and Africa · FY2022 · $22.60MAsia-Pacific · FY2022 · $36.15MAmericas · FY2022 · $69.56MEurope, Middle East, and Africa · FY2022 · $22.60MFY2023Americas · FY2023 · $105.41MUnited States · FY2023 · $100.50MEurope, Middle East, and Africa · FY2023 · $40.66MAsia-Pacific · FY2023 · $54.45MAmericas · FY2023 · $105.41MEurope, Middle East, and Africa · FY2023 · $40.66MFY2024Americas · FY2024 · $78.71MUnited States · FY2024 · $75.30MEurope, Middle East, and Africa · FY2024 · $34.59MAsia-Pacific · FY2024 · $40.71MFY2025Americas · FY2025 · $72.80MUnited States · FY2025 · $69.70MEurope, Middle East, and Africa · FY2025 · $44.05MAsia-Pacific · FY2025 · $43.16M
LineFY2025ShareChange
Americas$72.80M45%−7.5%
United States$69.70M44%−7.4%
Europe, Middle East, and Africa$44.05M28%+27.3%
Asia-Pacific$43.16M27%+6.0%
Americas———
Europe, Middle East, and Africa———
Total$160.01M

From the 10-K filed Feb 25, 2026PACB

Laboratory analytical instruments

Pacific Biosciences of California, Inc. is the 11th largest of the 25 covered companies the SEC files under this code, by revenue. SIC 3826

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Pacific Biosciences of California, Inc. · CIK 1299130 · Engraved from SEC EDGAR